Anti-TNF Therapeutics for the Treatment of Sarcoidosis

References

• IannuzziMC,Rybicki BA, Teirstein AS: sarcoidosis. N. Engl. J. Med. 357(21), 2153–2165 (2007).
   PubMed Web of Science ®Google Scholar
• Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am. J. Respir. Crit. Care Med. 160(2), 736–755 (1999).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 361(9363), 1111–1118 (2003).
   PubMed Web of Science ®Google Scholar
• Dastoori M, Fedele S, Leao JC, Porter SR. Sarcoidosis: a clinically orientated review. J. Oral Pathol. Med. 42(4), 281–289 (2013).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Teirstein AS, Judson MA et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am. J. Respir. Crit. Care Med. 164(10 Pt 1), 1885–1889 (2001).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 183(5), 573–581 (2011).
   PubMed Web of Science ®Google Scholar
• Rao DA, Dellaripa PF. Extrapulmonary manifestations of sarcoidosis. Rheum. Dis. Clin. North Am. 39(2), 277–297 (2013).
   PubMed Web of Science ®Google Scholar
• Israel-Biet D, Valeyre D. Diagnosis of pulmonary sarcoidosis. Curr. Opin. Pulm. Med. 19(5), 510–515 (2013).
   PubMed Web of Science ®Google Scholar
• Heinle R, Chang C. Diagnostic criteria for sarcoidosis. Autoimmun. Rev. 13(4–5), 383–387 (2014).
   PubMed Web of Science ®Google Scholar
• Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet (2013).
   PubMed Web of Science ®Google Scholar
• Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am. Rev. Respir. Dis. 130(1), 29–32 (1984).
   PubMedGoogle Scholar
• Morimoto T, Azuma A, Abe S et al. Epidemiology of sarcoidosis in Japan. Eur. Respir. J. 31(2), 372–379 (2008).
   PubMed Web of Science ®Google Scholar
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc. Diffuse Lung Dis. 29(2), 119–127 (2012).
   PubMed Web of Science ®Google Scholar
• Judson MA, Thompson BW, Rabin DL et al. The diagnostic pathway to sarcoidosis. Chest 123(2), 406–412 (2003).
   PubMed Web of Science ®Google Scholar
• Grunewald J. Genetics of sarcoidosis. Curr. Opin. Pulm. Med. 14(5), 434–439 (2008).
   PubMed Web of Science ®Google Scholar
• Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest 139(1), 144–150 (2011).
   PubMed Web of Science ®Google Scholar
• Rybicki BA, Major M, Popovich J Jr , Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am. J. Epidemiol. 145(3), 234–241 (1997).
   PubMed Web of Science ®Google Scholar
• James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann. NY Acad. Sci. 278, 321–334 (1976).
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Ohmichi M, Hiraga Y, Lofroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc. Diffuse Lung Dis. 13(2), 159–166 (1996).
   PubMed Web of Science ®Google Scholar
• Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am. J. Med. 100(4), 423–427 (1996).
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Huie TJ et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am. J. Respir. Crit. Care Med. 183(11), 1524–1530 (2011).
   PubMed Web of Science ®Google Scholar
• Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol. Jpn 43(7–8), 372–376 (1993).
   PubMedGoogle Scholar
• Iwai K, Sekiguti M, Hosoda Y et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 11(1), 26–31 (1994).
   PubMedGoogle Scholar
• Siltzbach LE, James DG, Neville E et al. Course and prognosis of sarcoidosis around the world. Am. J. Med. 57(6), 847–852 (1974).
   PubMed Web of Science ®Google Scholar
• Prasse A, Georges CG, Biller H et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin. Exp. Immunol. 122(2), 241–248 (2000).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J. Lab. Clin. Med. 115(1), 36–42 (1990).
   PubMed Web of Science ®Google Scholar
• Pantelidis P, McGrath DS, Southcott AM, du Bois RM. Single-cell analysis: a novel approach to tumour necrosis factor-alpha synthesis and secretion in sarcoidosis. Eur. Respir. J. 20(5), 1179–1184 (2002).
   PubMed Web of Science ®Google Scholar
• Dai H, Guzman J, Chen B, Costabel U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 127(1), 251–256 (2005).
   PubMed Web of Science ®Google Scholar
• Zissel G, Prasse A, Muller-Quernheim J. Immunologic response of sarcoidosis. Semin. Respir. Crit. Care. Med. 31(4), 390–403 (2010).
   PubMed Web of Science ®Google Scholar
• Broos CE, van Nimwegen M, Hoogsteden HC, Hendriks RW, Kool M, van den Blink B. Granuloma formation in pulmonary sarcoidosis. Front. Immunol. 4, 437 (2013).
   PubMedGoogle Scholar
• Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 305(4), 391–399 (2011).
   PubMed Web of Science ®Google Scholar
• Lugo-Villarino G, Hudrisier D, Benard A, Neyrolles O. Emerging trends in the formation and function of tuberculosis granulomas. Front. Immunol. 3, 405 (2012).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann. Rheum. Dis. 61(Suppl. 2), ii54–ii58 (2002).
   PubMedGoogle Scholar
• Reich JM. On the nature of sarcoidosis. Eur. J. Intern. Med. 23(2), 105–109 (2012).
   PubMed Web of Science ®Google Scholar
• Iannuzzi MC. Genetics of sarcoidosis. Semin. Respir. Crit. Care. Med. 28(1), 15–21 (2007).
   PubMed Web of Science ®Google Scholar
• Rybicki BA, Iannuzzi MC, Frederick MM et al. Familial aggregation of sarcoidosis. A case–control etiologic study of sarcoidosis (ACCESS). Am. J. Respir. Crit. Care Med. 164(11), 2085–2091 (2001).
   PubMed Web of Science ®Google Scholar
• van Moorsel CH, Christiani DC. Genetic susceptibility to sarcoidosis, a chronic inflammatory disorder. Am. J. Respir. Crit. Care Med. 186(9), 816–818 (2012).
   PubMed Web of Science ®Google Scholar
• Muller-Quernheim J, Prasse A, Zissel G. Pathogenesis of sarcoidosis. Presse Med. 41(6 Pt 2), e275–e287 (2012).
   PubMedGoogle Scholar
• Drent M, Cremers JP, Jansen TL. Pulmonology meets rheumatology in sarcoidosis: a review on the therapeutic approach. Curr. Opin. Rheumatol. 26(3), 276–284 (2014).
   PubMed Web of Science ®Google Scholar
• Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir. Med. 102(1), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur. Respir. J. 28(3), 627–636 (2006).
   PubMed Web of Science ®Google Scholar
• Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst. Rev. (2)(2), CD001114 (2005).
   Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 121(1), 24–31 (2002).
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, van Moorsel CH, Deneer VH, Grutters JC. Current therapy in sarcoidosis, the role of existing drugs and future medicine. Inflamm. Allergy Drug Targets 12(6), 369–377 (2013).
   PubMedGoogle Scholar
• Vorselaars AD, Wuyts WA, Vorselaars VM et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 144(3), 805–812 (2013).
   PubMed Web of Science ®Google Scholar
• Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2(5), 364–371 (2002).
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334(26), 1717–1725 (1996).
   PubMed Web of Science ®Google Scholar
• Kasahara K, Kobayashi K, Shikama Y et al. The role of monokines in granuloma formation in mice: the ability of interleukin 1 and tumor necrosis factor-alpha to induce lung granulomas. Clin. Immunol. Immunopathol. 51(3), 419–425 (1989).
   PubMedGoogle Scholar
• Marino MW, Dunn A, Grail D et al. Characterization of tumor necrosis factor-deficient mice. Proc. Natl Acad. Sci. USA 94(15), 8093–8098 (1997).
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168(9), 4620–4627 (2002).
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am. J. Respir. Crit. Care Med. 156(5), 1586–1592 (1997).
   PubMed Web of Science ®Google Scholar
• Braam AW, de Haan SN, Vorselaars AD et al. Influence of repeated maximal exercise testing on biomarkers and fatigue in sarcoidosis. Brain Behav. Immun. 33, 57–64 (2013).
   PubMed Web of Science ®Google Scholar
• Baydur A, Alavy B, Nawathe A, Liu S, Louie S, Sharma OP. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin. Respir. J. 5(3), 156–164 (2011).
   PubMed Web of Science ®Google Scholar
• Song GG, Kim JH, Lee YH. Associations between TNF-alpha -308 A/G and lymphotoxin-alpha +252 A/G polymorphisms and susceptibility to sarcoidosis. a meta-analysis. Mol. Biol. Rep. 41(1), 259–267 (2014).
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens 75(3), 262–268 (2010).
   PubMedGoogle Scholar
• Grutters JC, Sato H, Pantelidis P et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am. J. Respir. Crit. Care Med. 165(8), 1119–1124 (2002).
   PubMed Web of Science ®Google Scholar
• Medica I, Kastrin A, Maver A, Peterlin B. Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis. J. Hum. Genet. 52(10), 836–847 (2007).
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Cremers JP, Nelemans PJ et al. Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur. Respir. J. (2014).
   PubMed Web of Science ®Google Scholar
• Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am. J. Respir. Crit. Care Med. 169(6), 696–702 (2004).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 122(1), 227–232 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen YT, Dupuy A, Cordoliani F et al. Treatment of cutaneous sarcoidosis with thalidomide. J. Am. Acad. Dermatol. 50(2), 235–241 (2004).
   PubMed Web of Science ®Google Scholar
• Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 23(1), 51–57 (2006).
   PubMed Web of Science ®Google Scholar
• Fazzi P, Manni E, Cristofani R et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed. Pharmacother. 66(4), 300–307 (2012).
   PubMed Web of Science ®Google Scholar
• Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. 155(5), 1665–1669 (1997).
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana J, Babaali H et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 26(2), 121–131 (2009).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch. Dermatol. 148(2), 262–264 (2012).
   PubMedGoogle Scholar
• Utz JP, Limper AH, Kalra S et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124(1), 177–185 (2003).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128(2), 1062–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 23(3), 201–208 (2006).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. 174(7), 795–802 (2006).
   PubMed Web of Science ®Google Scholar
• van Rijswijk HNAJ, Vorselaars ADM, Ruven HJT et al. Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment. Exp. Opin. Orphan Drugs 1(6), 437–443 (2013).
   Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U et al. Efficacy of infliximab in extrapulmonary sarcoidosis. results from a randomised trial. Eur. Respir. J. 31(6), 1189–1196 (2008).
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 83(3), 218–224 (2012).
   PubMed Web of Science ®Google Scholar
• Russell E, Luk F, Manocha S, Ho T, O’Connor C, Hussain H. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin. Arthritis Rheum. 43(1), 119–124 (2013).
   PubMed Web of Science ®Google Scholar
• Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J. Am. Acad. Dermatol. 68(5), 765–773 (2013).
   PubMed Web of Science ®Google Scholar
• Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 250(5), 713–720 (2012).
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 31(1), 46–54 (2014).
   PubMed Web of Science ®Google Scholar
• Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir. Med. 91(1), 31–39 (1997).
   PubMed Web of Science ®Google Scholar
• Ye Q, Chen B, Tong Z et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur. Respir. J. 28(4), 824–831 (2006).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin. Chest Med. 29(3), 533–548, ix-x (2008).
   PubMed Web of Science ®Google Scholar
• Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am. J. Respir. Crit. Care Med. 159(2), 508–511 (1999).
   PubMed Web of Science ®Google Scholar
• Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 124(4), 1526–1532 (2003).
   PubMed Web of Science ®Google Scholar
• Katakami Y, Nakao Y, Koizumi T, Katakami N, Ogawa R, Fujita T. Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP. Immunology 64(4), 719–724 (1988).
   PubMed Web of Science ®Google Scholar
• Remicade® (infliximab), prescribing information. Centocor, Inc., PA, USA (2006).
   Google Scholar
• Judson MA, Baughman RP, Costabel U, Mack M, Barnathan ES. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir. Med. 108(1), 189–194 (2014).
   PubMed Web of Science ®Google Scholar
• Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27(4), 399–413 (2007).
   PubMed Web of Science ®Google Scholar
• Barnabe C, McMeekin J, Howarth A, Martin L. Successful treatment of cardiac sarcoidosis with infliximab. J. Rheumatol. 35(8), 1686–1687 (2008).
   PubMed Web of Science ®Google Scholar
• Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J. Neurol. Neurosurg. Psychiatry. 81(3), 241–246 (2010).
   PubMed Web of Science ®Google Scholar
• Pereira J, Anderson NE, McAuley D, Bergin P, Kilfoyle D, Fink J. Medically refractory neurosarcoidosis treated with infliximab. Intern. Med. J. 41(4), 354–357 (2011).
   PubMed Web of Science ®Google Scholar
• Hasni SA, Kunz D, Finzel K, Gruber BL. Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Spine (Phila Pa. 1976) 35(18), E904–E907 (2010).
   PubMed Web of Science ®Google Scholar
• Humira® (adalimumab), prescribing information. Abbott Laboratories, IL, USA (2007).
   Google Scholar
• Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin. Respir. J. 6(4), 238–247 (2012).
   PubMed Web of Science ®Google Scholar
• Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J. Med. Case Rep. 3, 8573 (2009).
   PubMedGoogle Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D et al. Adalimumab therapy for refractory uveitis: a pilot study. J. Ocul. Pharmacol. Ther. 24(3), 351–361 (2008).
   PubMed Web of Science ®Google Scholar
• Enbrel® (etanercept), precribing information. Immunex Corp., CA, USA (2007).
   Google Scholar
• Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354(9194), 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340(4), 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2(6), 817–833 (2010).
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49(7), 1215–1228 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 10(3), 308–315 (2010).
   PubMed Web of Science ®Google Scholar
• Ruspi G, Schmidt EM, McCann F et al. TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-kappaB pathways and signals TRAF2 protein degradation in macrophages. Cell. Signal. 26(4), 683–690 (2013).
   PubMed Web of Science ®Google Scholar
• Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9(6), 482–493 (2010).
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5(10), 392–399 (1995).
   PubMed Web of Science ®Google Scholar
• Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT. Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes. J. Inflamm. (London) 9(1), 38 (2012).
   Google Scholar
• Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301(2), 418–426 (2002).
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128(2), 376–392 (2005).
   PubMed Web of Science ®Google Scholar
• Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21(3), 251–258 (2005).
   PubMed Web of Science ®Google Scholar
• Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124(7), 1774–1785 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Highlights in anti-tumor necrosis factor monitoring. Gastroenterol. Hepatol. 8(7 Suppl. 4), 1–12 (2012).
   Google Scholar
• Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J. Investig. Dermatol. Symp. Proc. 12(1), 9–15 (2007).
   PubMedGoogle Scholar
• Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J. Rheumatol. Suppl. 74, 13–18 (2005).
   PubMedGoogle Scholar
• Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum. 34(5 Suppl. 1), 12–18 (2005).
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19), 2275–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Fellermann K. Adverse events of tumor necrosis factor inhibitors. Dig. Dis. 31(3–4), 374–378 (2013).
   PubMed Web of Science ®Google Scholar
• Pallavicini FB, Caporali R, Sarzi-Puttini P et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun. Rev. 9(3), 175–180 (2010).
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 127(3), 1064–1071 (2005).
   PubMed Web of Science ®Google Scholar
• Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann. Rheum. Dis. 63(3), 318–320 (2004).
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Sjogren EV, van Moorsel CH, Grutters JC. Bilateral vocal cord carcinoma in a sarcoidosis patient during Infliximab therapy. Case Rep. Pulmonol. 2013, 308092 (2013).
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J. Rheumatol. Suppl. 91, 47–55 (2014).
   PubMedGoogle Scholar
• Gupta D, Kumar S, Aggarwal AN, Verma I, Agarwal R. Interferon gamma release assay (QuantiFERON-TB Gold In Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc. Diffuse Lung Dis. 28(2), 95–101 (2011).
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 34(1), 51–58 (2011).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348(7), 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124(4), 917–924 (2003).
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84(5), 548–558 (2008).
   PubMed Web of Science ®Google Scholar
• Xu Z, Seitz K, Fasanmade A et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J. Clin. Pharmacol. 48(6), 681–695 (2008).
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9), 1552–1563 (1998).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J. Pediatr. Gastroenterol. Nutr. 38(5), 502–508 (2004).
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 146 3, 681–688.e1 (2013).
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann. Rheum. Dis. 71(11), 1914–1915 (2012).
   PubMed Web of Science ®Google Scholar
• Tong D, Manolios N, Howe G, Spencer D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern. Med. J. 42(1), 89–94 (2012).
   PubMed Web of Science ®Google Scholar
• Daien CI, Monnier A, Claudepierre P et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48(8), 883–886 (2009).
   PubMed Web of Science ®Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 111(3), 623–631 (1997).
   PubMed Web of Science ®Google Scholar
• Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 14(4), 522–528 (2009).
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Verwoerd A, van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur. Respir. J. 43(2), 602–609 (2014).
   PubMed Web of Science ®Google Scholar
• Korenromp IH, Heijnen CJ, Vogels OJ, van den Bosch JM, Grutters JC. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 140(2), 441–447 (2011).
   PubMed Web of Science ®Google Scholar
• Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin. Chem. 49(9), 1510–1517 (2003).
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc. Diffuse Lung Dis. 25(2), 143–149 (2008).
   PubMed Web of Science ®Google Scholar
• Keijsers RG, van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur. Respir. J. 41(3), 743–751 (2013).
   PubMed Web of Science ®Google Scholar
• Mostard RL, van Kroonenburgh MJ, Drent M. The role of the PET scan in the management of sarcoidosis. Curr. Opin. Pulm. Med. 19(5), 538–544 (2013).
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Grutters JC, Thomeer M et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q. J. Nucl. Med. Mol. Imaging 55(1), 66–71 (2011).
   PubMed Web of Science ®Google Scholar
• Marotte H, Miossec P. Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis. Joint Bone Spine 77(4), 297–305 (2010).
   PubMed Web of Science ®Google Scholar
• Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 48(7), 1849–1852 (2003).
   PubMedGoogle Scholar
• De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 21(2), 127–136 (2004).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Culver DA et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 29(2), 90–98 (2012).
   PubMed Web of Science ®Google Scholar